A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin
- PMID: 10683053
- DOI: 10.1001/jama.283.6.749
A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin
Abstract
Context: Large variations exist among hospitals in the use of treatment resources for community-acquired pneumonia (CAP). Lack of a common approach to the diagnosis and treatment of CAP has been cited as an explanation for these variations.
Objective: To determine if use of a critical pathway improves the efficiency of treatment for CAP without compromising the well-being of patients.
Design: Multicenter controlled clinical trial with cluster randomization and up to 6 weeks of follow-up.
Setting: Nineteen teaching and community hospitals in Canada.
Patients: A total of 1743 patients with CAP presenting to the emergency department at 1 of the participating institutions between January 1 and July 31, 1998.
Intervention: Hospitals were assigned to continue conventional management (n = 10) or implement the critical pathway (n = 9), which consisted of a clinical prediction rule to guide the admission decision, levofloxacin therapy, and practice guidelines.
Main outcome measures: Effectiveness of the critical pathway, as measured by health-related quality of life on the Short-Form 36 Physical Component Summary (SF-36 PCS) scale at 6 weeks; and resource utilization, as measured by the number of bed days per patient managed (BDPM).
Results: Quality of life and the occurrence of complications, readmission, and mortality were not different for the 2 strategies; the 1-sided 95% confidence limit of the between-group difference in the SF-36 PCS change score was 2.4 points, which was within a predefined 3-point boundary for equivalence. Pathway use was associated with a 1.7-day reduction in BDPM (4.4 vs 6.1 days; P = .04) and an 18% decrease in the admission of low-risk patients (31% vs 49%; P = .01). Although inpatients at critical pathway hospitals had more severe disease, they required 1.7 fewer days of intravenous therapy (4.6 vs 6.3 days; P = .01) and were more likely to receive treatment with a single class of antibiotic (64% vs 27%; P<.001).
Conclusion: In this study, implementation of a critical pathway reduced the use of institutional resources without causing adverse effects on the well-being of patients.
Comment in
- ACP J Club. 2000 Sep-Oct;133(2):72
-
A critical pathway for treatment of community-acquired pneumonia.JAMA. 2000 May 24-31;283(20):2654-5. doi: 10.1001/jama.283.20.2654. JAMA. 2000. PMID: 10819937 No abstract available.
Similar articles
-
[Community acquired pneumonia in the emergence department--do standardized care bundles improve quality of care?].Anasthesiol Intensivmed Notfallmed Schmerzther. 2015 Feb;50(2):92-101. doi: 10.1055/s-0040-100588. Epub 2015 Feb 27. Anasthesiol Intensivmed Notfallmed Schmerzther. 2015. PMID: 25723603 Review. German.
-
Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.Curr Med Res Opin. 2010 Feb;26(2):355-63. doi: 10.1185/03007990903482418. Curr Med Res Opin. 2010. PMID: 19995325
-
Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care?Pharmacoeconomics. 2004;22(7):413-20. doi: 10.2165/00019053-200422070-00001. Pharmacoeconomics. 2004. PMID: 15137880 Review.
-
A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.Pharmacotherapy. 2001 Jul;21(7 Pt 2):89S-94S. doi: 10.1592/phco.21.10.89s.34535. Pharmacotherapy. 2001. PMID: 11446524 Clinical Trial.
-
Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin.Clin Ther. 2000 Feb;22(2):250-64. doi: 10.1016/s0149-2918(00)88483-0. Clin Ther. 2000. PMID: 10743984 Clinical Trial.
Cited by
-
[Guidelines for the management of community pneumonia in adult who needs hospitalization].Med Intensiva. 2005 Feb;29(1):21-62. doi: 10.1016/S0210-5691(05)74199-1. Epub 2009 Jan 6. Med Intensiva. 2005. PMID: 38620135 Free PMC article. Spanish.
-
Factors Associated with Hospitalized Community-Acquired Pneumonia among Elderly Patients Receiving Home-Based Care.Healthcare (Basel). 2024 Feb 8;12(4):443. doi: 10.3390/healthcare12040443. Healthcare (Basel). 2024. PMID: 38391817 Free PMC article.
-
ICU Utilization After Implementation of Minor Severe Pneumonia Criteria in Real-Time Electronic Clinical Decision Support.Crit Care Med. 2024 Mar 1;52(3):e132-e141. doi: 10.1097/CCM.0000000000006163. Epub 2023 Dec 29. Crit Care Med. 2024. PMID: 38157205
-
Usefulness of a predictive model to hospitalize patients with low-risk community-acquired pneumonia.Eur J Clin Microbiol Infect Dis. 2024 Jan;43(1):61-71. doi: 10.1007/s10096-023-04683-w. Epub 2023 Nov 8. Eur J Clin Microbiol Infect Dis. 2024. PMID: 37938500
-
The Interventions and Challenges of Antimicrobial Stewardship in the Emergency Department.Antibiotics (Basel). 2023 Oct 9;12(10):1522. doi: 10.3390/antibiotics12101522. Antibiotics (Basel). 2023. PMID: 37887223 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous